Phase II/III trial of WT1 peptide vaccine in patients with multiple myeloma

Trial Profile

Phase II/III trial of WT1 peptide vaccine in patients with multiple myeloma

Planning
Phase of Trial: Phase II/III

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs Galinpepimut S (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Aug 2015 Planned initiation date changed from 1 Sep 2015 to 1 Jan 2016 according to a Sellas Life Sciences media release.
    • 17 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top